Joaquin Seras Franzoso I am researcher and PI at the Drug Delivery & Targeting Group belonging to the "Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation - AVANT " eCORE at Vall d'Hebron Institute of Research (VHIR). I combine this main activity with acting as associate lecturer at the Autonomous University of Barcelona (UAB). Instituciones de las que forman parte Investigador/a principal Bioquímica Clínica, Vehiculización de Fármacos y Terapia Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Email Joaquin Seras Franzoso LinkedIn Twitter Orcid Email Instituciones de las que forman parte Investigador/a principal Bioquímica Clínica, Vehiculización de Fármacos y Terapia Vall Hebron Institut de Recerca I am researcher and PI at the Drug Delivery & Targeting Group belonging to the "Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation - AVANT " eCORE at Vall d'Hebron Institute of Research (VHIR). I combine this main activity with acting as associate lecturer at the Autonomous University of Barcelona (UAB).
I performed my PhD at the Autonomous University of Barcelona (UAB, 2012). There, I focused on the development of first-in-class biomedical uses for bacterial Inclusion Bodies (IBs). IBs are recombinant protein deposits, between the nano- and micro scale, historically discarded as waste by products of protein production. My research studied the IB-exerted stimuli on mammalian cell interfaces when producing complex nanotopographies for tissue engineering. After my PhD I devoted myself to expand the catalogue of biomedical uses for IBs, as high added value biomaterials. I engineered IBs to be used as depots for the slow release of therapeutic proteins, polyvalent coatings and immunomodulatory particles. I moved to Vall d'Hebron Research Institute (VHIR) in 2015 awarded with an AECC post-doctoral fellowship. Here, I have continued my work in the nano-sphere. Particularly, I have participated in the development of Polymeric Micelles (PM) for the PM-mediated intracellular delivery of therapeutic antibodies, targeting cancer stem cell intrinsic drug resistance. In parallel, I started to explore the potential of extracellular vesicles (EVs). First, as central mediators of intercellular communication with roles in cancer cell plasticity regulation and premetastatic niche conditioning. Secondly, exploiting EVs capacity as protein delivery systems. In this regard, I focused on the generation of protein therapeutics loaded in vivo into EVs. This approach combines protein production and NP functionalization in a single step with intended applications in rare diseases and cancer therapy. I have participated in >20 competitive projects with an accumulated funding of > 3 Milion euros (PI of two). This activity rendered >50 articles (hi=25) in international journals and >60 contributions to congresses. Complementing this activity I engaged teaching undergraduates (2010-2012 & 2021 - , AQU Lecturer accreditation) at UAB and mentoring master and PhD students.
Proyectos Evolvable platform for designing cancer treatment strategies using nanoparticles (EVO-NANO) IP: Ibane Abasolo Olaortua Colaboradores: Joaquin Seras Franzoso, Simon Schwartz Navarro, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Belen Garcia Prats Entidad financiadora: EUROPEAN COMMISSION Financiación: 568847.5 Referencia: EVO-NANO_H2020FETOPEN2017 Duración: 01/10/2018 - 31/03/2022 Terapia combinada mediante nuevos nanoconjugados terapéuticos contra Células Madre Tumorales en tumores de mamas triple negativos IP: Simon Schwartz Navarro Colaboradores: Laura García Latorre, Joaquin Seras Franzoso, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael Entidad financiadora: Instituto de Salud Carlos III Financiación: 123420 Referencia: PI17/02242 Duración: 01/01/2018 - 31/12/2020 (Nano) systems with active targeting to sensitize colorectal cancer stem cells to anti-tumoral treatment Target4Cancer IP: Simon Schwartz Navarro Colaboradores: Laura García Latorre, Joaquin Seras Franzoso, Diana Fernandes de Rafael Entidad financiadora: Instituto de Salud Carlos III Financiación: 143385 Referencia: AC15/00092 Duración: 01/01/2016 - 30/09/2019 NoCanTher: Nanomedicine Upscaling for Early Clinical Phases of Multimodal Cancer Therapy IP: Simon Schwartz Navarro Colaboradores: Ibane Abasolo Olaortua, Joaquin Seras Franzoso, Tamara Del Rio Higueras, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Olga Sánchez- Maroto Carrizo, Angelica Valderrama Rodríguez Entidad financiadora: EUROPEAN COMMISSION Financiación: 630633.55 Referencia: NOCANTHER_H2020NMP2015 Duración: 01/04/2016 - 30/09/2021 Paginación Primera página « Página anterior ‹ Página 1 Página 2 Página actual 3 Página 4 Siguiente página › Última página »
